Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Comparison of Clinicopathological Features of Patients with Two Spliceosome Gene Co-Mutations

Amy Song, Richard Shao, Lynn C. Moscinski, Julie Li, Mohammad Omar Hussaini, Le Wang, Hailing Zhang

Blood (2024) 144 (Supplement 1): 4599.

https://doi.org/10.1182/blood-2024-200961

Published: 2024

Journal Articles

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Blood (2024) 144 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2024-210599

Published: 2024

Journal Articles

A Deep-Learning Pipeline for Diagnosis of Myelodysplastic Syndromes/Neoplasms Using Bone Marrow Smears

Palak Dave, Jordan Rai, Ling Zhang, Mohammad Omar Hussaini, Mary Ellen Walker, Nancy Gillis, Mikkael A. Sekeres, Amy E. DeZern, Eric Padron, Rami S. Komrokji, Issam El Naqa

Blood (2024) 144 (Supplement 1): 4991.

https://doi.org/10.1182/blood-2024-207735

Published: 2024

Journal Articles

Comparison of the Clinicopathological Findings of Patients with SF3B1 / JAK2 , SF3B1 / Calr , or SF3B1 / MPL co-Mutations

Richard Shao, Hailing Zhang, Lynn C. Moscinski, Mohammad Omar Hussaini, Julie Li, Ahmed Arfa, Le Wang, Jinming Song

Blood (2024) 144 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2024-199880

Published: 2024

Journal Articles

A Large Cohort Study of 412 Patients with SRSF2/TET2 Co-Mutated Myeloid Neoplasms: The Molecular Landscape and Clinical Outcomes

Samuel G Cockey, Hailing Zhang, Mohammad Omar Hussaini, Ling Zhang, Lynn C. Moscinski, Ethan Yang, Jinming Song

Blood (2023) 142 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2023-186967

Published: 2023

Journal Articles

Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival

David A Sallman, MD, Najla Al Ali, M.Sc, Seongseok Yun, MD PhD, Eric Padron, MD, Jinming Song, MD PhD, Mohammad Omar Hussaini, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2018) 132 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2018-99-117297

Published: 2018

Journal Articles

Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia

Todd C. Knepper, PharmD, Yehuda E. Deutsch, MD, Chirag K Bhagat, PharmD, Justin M Watts, MD, Terrence J Bradley, MD, Wassim Samra, MD, Mohammad Omar Hussaini, MD, Kendra L. Sweet, MD, Chetasi Talati, MD, Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, David A Sallman, MD

Blood (2018) 132 (Supplement 1): 1524.

https://doi.org/10.1182/blood-2018-99-113088

Published: 2018

Journal Articles

Role of Somatic Mutations in Clonal Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Phase

Chetasi Talati, MD, Leidy Isenalumhe, MD, Andrew Kuykendall, MD, Bijal D. Shah, MD, Julio C. Chavez, MD, Mohammad Omar Hussaini, MD, Javier Pinilla-Ibarz, MD PhD, Kendra L. Sweet, MD

Blood (2017) 130 (Supplement 1): 1587.

https://doi.org/10.1182/blood.V130.Suppl_1.1587.1587

Published: 2017

Journal Articles

TP53 Mutations Are a Rare Event in Primary Myelofibrosis, Associated with TET2 Mutations, and Suggest Poor Clinical Outcome

Mohammad Omar Hussaini, MD, Jinming Song, MD PhD, Rami S. Komrokji, MD, David A Sallman, MD, Andrew Kuykendall, MD, Eric Padron, MD, Sayeef Mirza, MD MPH, Ling Zhang, MD

Blood (2017) 130 (Supplement 1): 5270.

https://doi.org/10.1182/blood.V130.Suppl_1.5270.5270

Published: 2017

Journal Articles

Presence of MDS-Related Cytogenetic Abnormalities Predicts Worse Outcomes in Primary Myelofibrosis Compared to Patients with Del(13q)

Mohammad Omar Hussaini, MD, Jinming Song, MD PhD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Andrew Kuykendall, MD, Sayeef Mirza, MD MPH, Ling Zhang, MD

Blood (2017) 130 (Supplement 1): 5275.

https://doi.org/10.1182/blood.V130.Suppl_1.5275.5275

Published: 2017

Journal Articles

Clinical Utility of Molecular Profiling in Higher Risk MDS Treated with Azacitidine: Can We Tailor Therapy Accordingly?

David Sallman, MD, Eric Padron, MD, Jinming Song, MD PhD, Mohammad Omar Hussaini, MD, Christine Vaupel, PhD, Najla H Al Ali, Jeffrey E. Lancet, MD, Jeff Hall, PhD, Alan F List, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1984.

https://doi.org/10.1182/blood.V128.22.1984.1984

Published: 2016

Journal Articles

Large Cohort Analysis of Targeted NGS Mutations and Cytogenetic Abnormalities in Hematologic Malignancies

Mohammad Omar Hussaini, MD, Haipeng Shao, MD, PhD, Lynn C. Moscinski, MD, Jinming Song, MD PhD

Blood (2015) 126 (23): 1406.

https://doi.org/10.1182/blood.V126.23.1406.1406

Published: 2015

Journal Articles

Refining Triage to Polycythaemia Vera or Primary Myelofibrosis Based on Targeted Molecular Profiling By Clinical Next Generation Sequencing

Song Jinming, MD, PhD, Mohammad Omar Hussaini, MD, Haipeng Shao, MD, PhD, Eric Padron, MD, Jeffrey E Lancet, MD, Rami S. Komrokji, MD, Ling Zhang, MD, Lynn C. Moscinski, MD

Blood (2015) 126 (23): 4076.

https://doi.org/10.1182/blood.V126.23.4076.4076

Published: 2015

NARROW

Comparison of Clinicopathological Features of Patients with Two Spliceosome Gene Co-Mutations

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

A Deep-Learning Pipeline for Diagnosis of Myelodysplastic Syndromes/Neoplasms Using Bone Marrow Smears

Comparison of the Clinicopathological Findings of Patients with SF3B1 / JAK2 , SF3B1 / Calr , or SF3B1 / MPL co-Mutations

A Large Cohort Study of 412 Patients with SRSF2/TET2 Co-Mutated Myeloid Neoplasms: The Molecular Landscape and Clinical Outcomes

Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival

Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia

Role of Somatic Mutations in Clonal Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Phase

TP53 Mutations Are a Rare Event in Primary Myelofibrosis, Associated with TET2 Mutations, and Suggest Poor Clinical Outcome

Presence of MDS-Related Cytogenetic Abnormalities Predicts Worse Outcomes in Primary Myelofibrosis Compared to Patients with Del(13q)

Clinical Utility of Molecular Profiling in Higher Risk MDS Treated with Azacitidine: Can We Tailor Therapy Accordingly?

Large Cohort Analysis of Targeted NGS Mutations and Cytogenetic Abnormalities in Hematologic Malignancies

Refining Triage to Polycythaemia Vera or Primary Myelofibrosis Based on Targeted Molecular Profiling By Clinical Next Generation Sequencing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only